The AlphaLISA® SureFire® Ultra™ p-STAT5 (Tyr694/699) HV (high volume) assay is a sandwich immunoassay for quantitative detection of phospho-STAT5 (phosphorylated on Tyr694/699) in cellular lysates using Alpha Technology. This kit replaces ALSU-PST5-A-HV. ALSU-PST5-A-HV is no longer available as the antibody(ies) have been discontinued by the supplier. A new antibody pair has been selected and validated to make this new version, with a similar or slightly improved performance over the initial version. Comparative data are included in the manuals of the new kits.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The AlphaLISA® SureFire® Ultra™ p-STAT5 (Tyr694/699) assay is a sandwich immunoassay for quantitative detection of phospho-STAT5 (phosphorylated on Tyr694/699) in cellular lysates using Alpha Technology.
In the AlphaLISA® SureFire® Ultra™ assay, Donor beads are coated with streptavidin to capture one of the antibodies, which is biotinylated. Acceptor beads are coated with a proprietary CaptSure™ agent that immobilizes the other antibody, labeled with a CaptSure™ tag. In the presence of phosphorylated protein, the two antibodies bring the Donor and Acceptor beads close together, generating signal. The amount of light emission is directly proportional to the amount of phosphoprotein present in the sample.
AlphaLISA® SureFire® Ultra™ kits are compatible with:
Alpha SureFire® kits can be used for:
|Assay Target Class||Phosphoprotein|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA SureFire Ultra|
|Second Messenger Release||Protein phosphorylation|
|Shipping Condition||Blue Ice|
|Unit Size||10,000 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater ...
In this application note, we demonstrate an efficient cell-based workflow for the assessment of EGF treatment effects in a cellular model of human skin cancer.
Treatment effects on several intracellular signaling pathways were examined using PerkinElmer’s homogeneous, no-wash AlphaLISA ...